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Regulation of Dietary Supplements: Five Years of
DSHEA
LAURA A. W. KHATCHERESSIAN*
There is no alternative medicine. There is only scientifically proven evidence-based medicine
supported by solid data or unproven medicine, for which scientific evidence is lacking.'
I. INTRODUCTION
On October 25, 1994, President Clinton signed into law the Dietary Supplement
Health and Education Act (DSHEA), 2 passed unanimously by both houses of Con-
gress. This law radically changed the regulatory landscape for the sale and labeling of
dietary supplements, restricting the Food and Drug Administration's (FDA's) author-
ity in certain ways, and encouraging the sale of dietary supplements, including vita-
mins, minerals, herbs, botanicals, and amino acids.
This article examines DSHEA and discusses current FDA attempts to regulate di-
etary supplements. Part II provides a brief background and discusses FDA's concerns
and attitude toward dietary supplements before the passage of DSHEA. Part III dis-
cusses recent congressional actions that have influenced FDA's ability to regulate di-
etary supplements: passage of the Nutrition Labeling and Education Act (NLEA), the
moratorium imposed on use of NLEA to restrict dietary supplement labels, and passage
of DSHEA in 1994. Part IV describes the regulatory changes brought about by DSHEA.
Part V reviews concerns stemming from the recent growth in the dietary supple-
ment industry and from the regulatory framework currently in place. Concerns about
consumer safety and the efficacy of dietary supplements are discussed, and some recent
reports of contamination of dietary supplements are reviewed. Part VI chronicles FDA
actions since DSHEA, and discusses how FDA is attempting to regulate dietary supple-
ments under DSHEA. The recent Cholestin® decision is analyzed, as is the U.S. Court of
Appeals for the D.C. Circuit's ruling that the First Amendment restricts FDA's ability to
prevent manufacturers from placing certain health claims on their supplements.
Finally, part VII offers a proposal that would increase consumer knowledge of di-
etary supplement safety and efficacy.' In the current situation, benign but useless prod-
ucts are shelved beside, and labeled similarly to, both useful products with real health
benefits and products that can be harmful. Even the thoughtful consumer is hard-pressed
to distinguish one product from another. Unfortunately, there seems little hope that
Congress will change the situation, absent some catastrophic public health event.
II. FDA CONCERNS AND REGULATION BEFORE DSHEA
FDA's concern about dietary supplements dates back to the 1938 passage of the
Federal Food, Drug, and Cosmetic Act (FDCA),4 although the level and focus of that
'Ms. Khatcheressian is an Associate at the law firm of Mezzullo & McCandlish, Richmond, Virginia. A
previous version of this article received Honorable Mention in the 1998-1999 H. Thomas Austern Memorial
Writing Competition sponsored by FDLI.
'Phil B. Fontanarosa, M.D. & George D. Lundberg, M.D., Alternative Medicine Meets Science, JAMA,
Nov. 11, 1998, at 1618-19.
2 Pub. L. No. 103-417, 108 Stat. 4325 (codified at 21 U.S.C. § 301 note (1994)).
3 The author views the current state of the law with considerable concern, and views the panoply of dietary
supplements currently available on the market with considerable skepticism.
4 Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended 21 U.S.C. §§ 301 et seq.).
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concern has changed over time.' Soon after the FDCA was passed, FDA established
detailed labeling requirements for foods marketed for "special dietary uses."6 These
rules remained effective until 1962 when FDA published regulations that proposed to
set minimum and maximum levels for dietary supplements, but withdrew them in the
face of consumer protest.7 FDA then attempted to regulate excessive dosages of vita-
mins as drugs through adjudication; this was an approach foreclosed by Congress.' In
the late 1970s, FDA again attempted to regulate high-level dosage vitamins as drugs
through adjudication, this time focusing on the toxic impacts of the products.9 The
federal courts, however, were not receptive to this approach, nor to the alternative
approach of regulating supplements as food additives. 0
As the number, availability of, and consumer interest in dietary supplements has
grown in the United States in recent decades," FDA has become more concerned about
and interested in how to regulate these products. In 1993, FDA made it clear that the
agency viewed its mission as ensuring that the products are safe and that "claims
made for their use are scientifically supported, truthful, not misleading, and otherwise
in accord with applicable legal standards."' 2
The agency is concerned with both "direct"' 3 and "indirect"' 4 effects. In addition,
health care professionals are concerned about the interactions of supplements with
prescription drugs.'" This should be considered in light of the recent information that
many consumers do not inform physicians about their use of dietary supplements. 6
Furthermore, FDA and the Federal Trade Commission (FTC) are interested in the
' The following brief review of historical regulatory efforts by FDA is not intended to be comprehensive.
Rather, it is intended to give a sense of the type of efforts made by FDA in the past to regulate dietary supplements.
6PETER Hurr & RICiARD MERRILL, FOOD & DRUG LAW CASES AND MATERIALS 212-21 (2d ed. 1991).
7 FDA focused on vitamin and mineral supplements at that time. The concern over herbals and amino acids
is relatively recent. See, e.g., HuTT & MERRILL, supra note 6, at 212-21; S. REP. No. 103-410, at 15 (1994).
1 In 1976, Congress passed the Health Research and Health Services Amendments (sometimes referred to
as the Proxmire/Rogers amendments) to the FDCA, Pub. L. No. 94-278, 90 Stat. 401 (codified in scattered
sections of 21 U.S.C. § § 301 et seq.) Title V of these amendments restricted FDA's authority over vitamin and
minerals, and added § 411 to the FDCA. 21 U.S.C. § 350 (as amended). That section prohibits FDA from
establishing maximum limits on the potency of vitamins or minerals, and forbids FDA from classifying a vitamin
or mineral product as a drug "solely because it exceeds the level of potency which the Secretary determines is
nutritionally rational or useful." Id. § 350(a)( I )(B).
'See National Nutritional Foods Ass'n v. Mathews, 557 F.2d 325 (2d Cir. 1977) (rejecting FDA's classi-
fication of high doses of vitamins A and D as drugs). But see Nutrilab, Inc. v. Schweiker, 713 F.3d 335 (7th Cir.
1983) (accepting FDA's classification of "starch blockers" as drugs).
'oSee, e.g., United States v. Two Plastic Drums, 984 F.2d 814 (7th Cir. 1993) (rejecting FDA's argument that
encapsulated black currant oil could be a "food additive," when the single active ingredient of the "food" was the
black currant oil itself); United States v. 29 Cartons of an Article of Food, 987 F.2d 33 (1 st Cir. 1993) (reaching
same conclusion on similar facts and characterizing FDA's interpretation of the FDCA as "nonsensical").
"See, e.g., Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690-91 (June 18, 1993) (noting
the increased use and availability of dietary supplements).
I2 Id. at 33,691.
'1 Id. (defining direct effects as "those adverse health effects directly attributable to the components of
dietary supplement products").
41d. (defining indirect effects as the problems that may arise "if the use of a supplement product delays the
diagnosis or treatment of a health disorder").
" See, e.g., Wayne B. Jonas, M.D., Alternative Medicine - Learning from the Past, Examining the
Present, Advancing to the Future, JAMA, Nov. 1I, 1998, at 1616-18 (noting that "[flifteen million Americans
are taking high-dose vitamins or herbal preparations along with prescription drugs, thereby risking adverse
effects from unknown interactions").
"6A recent study indicates that while use of alternative medicine (including treatment with dietary supple-
ments, such as high doses of vitamins or herbal remedies) and visits to alternative medicine practitioners have
increased markedly in recent years, only 38.5% of those who use alternative therapies discussed them with their
physician. Fontanarosa & Lundberg, supra note I, at 1618-19; see also Yitzhak Beigel et al., A Leading Ques-
tion, NEW ENG. J. MED., 827-30, n.4 (Sept. 17, 1998) (indicating that up to 72% of patients who use "unconven-
tional treatments" do not inform their physicians).
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prevention of consumer fraud, and are anxious to prevent a health-conscious public
from spending money on products that, even if benign, are not necessary or useful for
good health.' 7
While many of the ingredients in dietary supplements appear to be harmless or
even helpful, there are products that pose hazards. FDA's concern in the early 1990s
was galvanized by a 1989 outbreak of at least 1500 cases of eosinophilia myalgia
syndrome, resulting in thirty-eight deaths, that was caused by the use of supplements
containing the amino acid L-tryptophan.' t FDA's current concerns are prompted by
additional examples of harm resulting from dietary supplement use. For example,
from 1993 to 1997 fifteen deaths and approximately 400 "adverse reactions" were
attributed to the herbal dietary supplement ephedra.' 9
FDA's attempts to classify dietary supplements in such a way (as food additives or
as drugs) as to ensure some type of premarket approval of their safety, and possibly of
their efficacy, were not wholly successful. These efforts, however, drew the attention
of the dietary supplement industry and Congress.
III. CONGRESSIONAL ACTION AND REACTION
FDA's attempt to regulate dietary supplements in the 1980s was influenced by the
L-tryptophan calamity and agency concern over labels that made unsubstantiated claims
of health benefits.," Congressional passage of the NLEA2 ' provided a new avenue of
possibilities for FDA to regulate claims made by dietary supplements. The NLEA
allowed FDA to pass regulations requiring that specific information, including the
serving size, amount of certain nutrients, vitamins, or minerals, and information re-
lating to those substances, be placed on the labels of food products.22
The NLEA directed FDA to use a standard of "significant scientific agreement"
to decide whether foods could make "health claims." 3 The NLEA, however, specifi-
cally allowed FDA to recommend a different standard and approval procedure for
supplements.24 In December 199 1, FDA proposed implementing regulations that opted
to use the "significant scientific agreement" standard for dietary supplements, as well
as for foods." Using this standard, FDA rejected all but one health claim for supple-
ments.
2 6
In response to intense advocacy by the dietary supplement industry, Congress
passed a one-year moratorium on the application of the NLEA provisions to dietary
" See, e.g., Federal Trade Commission, Dietary Supplements: An Advertising Guidefor Industry (1998)
(visited Nov. 18, 1998) <www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
" See 58 Fed. Reg. at 33,691.
' See, e.g., Peter A. Vignuolo, The Herbal Street Drug Crisis: An Examination of the Dietary Supple-
ment Health and Education Act of 1994, 21 SETON HALL LEGIS. J. 200, 200-02 (1997). Evidence of reactions to
ephedra, an herbal extract that has been marketed "as an alternative, legal method of obtaining a drug-like high,"
convinced FDA to warn consumers against taking the product and propose rules for dietary supplements con-
taining ephedrine alkaloids. Id. at 201; Products That Consumers Inquire About (visited Mar. 24, 1999), avail-
able at <vm.cfsan. fda.gov/-dms/ds-prod.html> (citing Dietary Supplements Containing Ephedrine Alkaloids,
62 Fed. Reg. 30,678 (to be codified at 21 C.F.R. I 1) (June 4, 1997)).
20See Vignuolo, supra note 19, at 211, nn. 69-71.
2' Pub. L. No. 101-535, 104 Stat. 2353 (1990) (codified at 21 U.S.C. §§ 301 note, 321, 337, 343, 343
notes, 343-1, 343-1 note, 345, 371).
22 21 U.S.C. § 343 (NLEA § 2).
2321 U.S.C. § 343(r)(3)(B)(i) (NLEA § 3(a)).
24 NLEA § 3(b), 104 Stat. 2353, 2361.
21 S. REP. No. 103-410 at 15.
26 Id.
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supplements in 1992.27 In May 1991, however, FDA created a Task Force to "review
the agency's regulatory program for dietary supplements and to recommend improve-
ments. '28 The Task Force completed its report in May 1992 and submitted a recom-
mendation that at least some dietary supplements be regulated as drugs.2 9
The report and recommendations, however, were mooted largely by the efforts in
Congress to change the regulation of dietary supplements from 1993 to 1994. A sub-
stantial lobbying effort led by the dietary supplement industry,30 that continued after
the NLEA moratorium was enacted, eventually resulted in the passage of DSHEA.
Congress obviously was influenced by the grassroots lobbying effort of the dietary
supplement-consuming public (who were encouraged and, arguably, misinformed by
the dietary supplement industry).3' Congress also was angered by FDA's strained in-
terpretations of the FDCA in the black currant oil cases,32 and by FDA's lack of speed
in approving health claims for folic acid.33 A U.S. Senate report on DSHEA argued
that "FDA has tried to 'protect' the public against 'unsafe' products for which there is
no evidence that the product is unsafe," while acting to "restrict the information that
the public may receive about dietary supplements."34
IV. DSHEA: MAJOR CHANGES IN THE REGULATORY LANDSCAPE
DSHEA was touted by congressional promoters as balancing the consumer inter-
est in good health and nutrition against the government interest "in guaranteeing the
quality and safety of foods and products available to consumers"35 by providing ad-
equate and accurate information on dietary supplements so that consumers could make
informed choices, and by ensuring that unsafe products could be removed from the
marketplace.
3 6
DSHEA made some important changes in the regulatory framework. The three most
important aspects of DSHEA were: 1) providing a clear definition of a "dietary supple-
ment"; 2) changing the rules surrounding the labeling of dietary supplements; and 3)
shifting the burden of proof about a product's safety from the manufacturer to FDA.
A. Broadening the Definition of Dietary Supplement
DSHEA defined "dietary supplement" broadly to include any non-tobacco prod-
uct "intended to supplement the diet" that includes a vitamin, mineral, herb (or "other
botanical"), amino acid, "dietary substance for use by man to supplement the diet by
increasing the total dietary intake," or a "concentrate, metabolite, constituent, extract,
or combination of' any preceding substances.37 As discussed below, unless a dietary
21See Prescription Drug User Fee Act, Pub. L. No. 102-571, 106 Stat. 4491 (codified in scattered sections
of 21 U.S.C. §§ 301 et seq.).
2158 Fed. Reg. at 33,691.
291d. at 33,697 (citing findings of Task Force that the "primary intended use" of certain amino acid prod-
ucts "is for therapeutic rather than nutritional purposes").3
°See, e.g., Vignuolo, supra note 19, at 215-20; Dante E.A. Ramos, itamin Makers Try a Dose of
Lobbying, 25 NAT'L HEALTH J. 1879 (1993).
31 See Vignuolo, supra note 19, at 215-20 (arguing that the industry informed consumers that Congress
was considering a complete restriction of all dietary supplements).
31 See supra note 10.
"1S. REP. No. 103-410, at 16.
34 Id.
11 See, e.g., Statement by President William J. Clinton upon signing S. 784 (Oct. 25, 1994), reprinted in
1994 U.S.C.C.A.N. § 3523-1.
36
/d.
3721 U.S.C. § 321(fl)(DSHEA § 3(a)).
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supplement is "intended for use in the diagnosis, cure, mitigation, treatment or pre-
vention of disease," it is a food.3 8
The definition explicitly includes articles approved as new drugs that, prior to
that approval, were "marketed as a dietary supplement or as a food," unless FDA has
issued a regulation finding that the article was adulterated.39 The term "dietary supple-
ment" does not include "an article that is approved as a new drug," 4° if it was not
present in the food supply as a food or dietary supplement prior to its approval. Inter-
pretation of this language, and particularly the definition of "article," recently became
crucial in a case where FDA attempted to classify a dietary supplement as a drug
whose active ingredient chemically is identical to the active ingredient in an approved
prescription drug.4'
Displaying its disapproval of FDA's posture in the black currant oil cases, Con-
gress excluded dietary supplements from the definition of a food additive.42 Thus,
under the current definition, supplements are foods or drugs, based on their claims
and labeling. Congress, however, carved out specific exemptions from normal label-
ing rules for dietary supplements.
B. Narrowing "Labeling" to Exclude Point-of-Sale
Promotional Materials
Before DSHEA, FDA held the position that "labeling" of dietary supplements
included not only the claims printed on the actual product or its label, but also any
"other written, printed, or graphic matter"43 accompanying the product. Under this
definition, FDA could regulate any articles or materials touting the supplement's health
benefits, as long as the material "accompanied" the product. With DSHEA, however,
Congress changed this.
Section 5 of DSHEA specifically exempts from "labeling" any "publication, in-
cluding an article, a chapter in a book, or an official abstract of a peer-reviewed scien-
tific publication that appears in an article and was prepared by the author or the
editors of the publication, which is reprinted in its entirely.""4 The exemption does
require the publication not to be false or misleading, not to promote a particular brand
of a dietary supplement, to be displayed separately from the product itself, and to be
"displayed or presented.., so as to present a balanced view of the available scientific
information of a dietary supplement. 4
5
This section effectively removed the possibility that FDA could regulate a supple-
ment as a drug based on claims made in materials accompanying the product that the
substance was useful in the cure, mitigation, treatment, or prevention of any disease.
The clause provides that the materials must present a "balanced view of the available
scientific information" 46 about a substance; however, it is unclear how much weight
that provision carries. If the only "available scientific information" is non-clinical
3821 U.S.C. §§ 321 (ff)(3), 321(g). As discussed infra, a dietary supplement may make structure/function
claims. See id. § 341(r)(6).391d. § 321(ff)(3)(A).
4Id. § 321(ff)(3)(B).
4' See infra notes 82-92, and accompanying text.
4221 U.S.C. § 321(s) (DSHEA § 3(b)).
43 See 21 U.S.C. § 32 1(m) (general definition of labeling); see also 58 Fed. Reg. at 33,690.
-21 U.S.C. § 343-2(a) (DSHEA § 5).
4 Id. Congress also required that the publication "not have appended to it any information by sticker or any
other method." Id. § 343-2(a)(5).
IId. § 343-2(a)(3).
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trials performed by the manufacturers themselves, it seems consistent with the plain
language of the statute that no other information need be provided, even though the
studies done may not represent a scientific consensus.
DSHEA also detailed when the labels of dietary supplements would violate the
law. The labels of dietary supplements may make health claims describing "general
well-being from consumption of a nutrient or dietary ingredient, '47 claiming an im-
pact of a supplement on the "structure or function" of the body, or claiming a benefit
relating to a classical nutrient deficiency disease (subject to certain conditions), as
long as the manufacturer of the product has "substantiation" (which DSHEA neither
defined nor required to be submitted to FDA48) that the claim "is truthful and not
misleading. '49 In addition, the manufacturer must print on the label the following
disclaimer: "This statement has not been evaluated by the Food and Drug Administra-
tion. This product is not intended to diagnose, treat, cure, or prevent any
disease."50 Compliance with these provisions ensures that the supplement will not be
regulated as a drug."
FDA opted to regulate NLEA health claims "for both foods and dietary supple-
ments in the same way."52 Thus, a food or dietary supplement manufacturer wishing to
characterize the relationship of a nutrient listed on its label to a disease or health-
related condition must seek and obtain FDA's approval. That approval will be granted
only if there is "significant scientific agreement ... based on the totality of publicly
available scientific evidence"53 that the claim is supported. 4
C. Shifting the Burden of Proving Safety, or Lack Thereof, to FDA
The third important aspect of DSHEA was to shift the burden of proving safety
from the manufacturer to FDA. If a supplement was considered a food additive or a
new drug, the manufacturer would be required to prove the supplement was safe (and,
if a drug, effective for its intended use) - either by showing that the substance was
generally regarded as safe or by providing some clinical trials and studies showing
that the substance was safe under conditions of use. Because DSHEA defines dietary
supplements as a subset of foods, they are not required yet to undergo a premarket
approval process. If FDA is uncertain of a supplement's safety and wishes to remove it
from the market, it affirmatively must prove that the product would be harmful if
taken as recommended.5
47 Id. § 343(r)(6) (DSHEA § 6).48 See, e.g., Paula Kurtzweil, An FDA Guide to Dietary Supplements (visited Mar. 24, 1999), available
at <vm.cfsan.fda.gov/-dms/fdsupp.html> (noting that while a manufacturer "must be able to substantiate its
claim, it does not have to share the substantiation with FDA or make it publicly available"). Without any objec-
tive analysis of manufacturer "substantiation," it is unclear if the requirement of substantiation is an empty one.
9 21 U.S.C. § 343(r)(6) (DSHEA § 6).
5021 U.S.C. § 343(r)(6)(C).
5
"Id. § 321 (g)(D) (noting in part that a dietary supplement "for which a claim, subject to [the provisions
regulating misbranding under the FDCA], is made in accordance with the requirements of section 403(r) is not
a drug solely because the label or the labeling contains such a claim").
51 See 59 Fed. Reg. at 426 (codified at 21 C.F.R. § 101.14).
53 21 U.S.C. § 343(r) (DSHEA § 6(B)); see also 21 U.S.C. §§ 343(r)(3); 343(r)(5)(D) (exempting dietary
supplements from the process required for foods). FDA has approved several health claims for foods, such as the
statements that calcium helps to prevent osteoporosis and that folic acid helps pregnant women prevent their
children from being born with neural tube defects. Katherine E. Harris, Law Exempts Diet Supplements From
Labeling Rules (last modified Mar. 10, 1999),<www.legislate.com/xp/p-special/i- 1999031001/a-9210866071/
article.view> (quoting FDA spokeswoman).
4 The apparent conflict between the language of DSHEA and FDA's regulations regarding "health claims"
is discussed later in this paper.
5 21 U.S.C. § 342(f)(A) (noting that a dietary supplement is adulterated if it "presents a significant or
unreasonable risk of illness or injury"). Alternatively, if FDA determines that a product poses an "imminent
continued
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V. IMPACTS AND PROBLEMS OF DSHEA
The results of DSHEA are difficult to quantify, but it is clear that there has been
an explosion in the marketing and use of dietary supplements that could not have been
possible without the loosened regulatory structure of the Act. Americans spent ap-
proximately twelve billion dollars for all dietary supplements in 1997, and surveys
indicate that "more than half of the U.S. adult population" uses them. 6 Loosened
oversight under DSHEA has allowed small businesses to start selling substances such
as androstenedione (the hormone taken by baseball star Mark McGuire) in violation of
the relaxed DSHEA rules.57 Today, FDA estimates that there are 25,000 to 30,000 supple-
ment products available. The growth in some herbal supplements is phenomenal. 9
Five years of DSHEA have brought to light three major areas of concern: 1)
problems involving definitions of "dietary supplements;" 2) problems involving the
claims made by supplement manufacturers; and 3) problems involving the purity and
consistency of the supplements.
A. Definitional Concerns
The definition of "dietary supplement," understood in 1994 to be broad, has turned
out to include not only the vitamins, minerals, and herbs that Congress may have had
in mind when it passed DSHEA, but also substances that are sold as prescription
drugs in other countries, and even in the United States.' While these products fall
hazard to public safety," FDA immediately may remove it from the market, but then must hold a proceeding to
affirm or negate that decision. Id. § 342(f)(C). FDA also has authority to prohibit the marketing of a new dietary
ingredient "for which there is inadequate information to provide reasonable assurance that such ingredient does
not present a significant or unreasonable risk of illness or injury." Id. § 342(f)(B). The term "new dietary ingre-
dient," however, does not reach most dietary supplements. 21 U.S.C. § 350b defines "new dietary ingredient"
such that only those supplements for which the dietary ingredients were not present in the food supply as an
article used for food or there is some "history of use or other evidence of safety" for the new dietary ingredient are
"adulterated" under § 342(0. Furthermore, the term "new dietary ingredient" only applies to those ingredients
not marketed in the United States before passage of the DSHEA in October 1994. Id. § 350b(c).
56 Katherine E. Harris, Issue Focus: Lawmakers Push Door Open for Dietary Supplements (last modi-
fied Mar. 10, 1999) <www.legislate.com/xp/p-specialli-current/a-921085778/article. view> (noting that "sales
of nutritional supplements are up almost 30 percent since 1995"); Jane E. Henney, M.D., Statement ofJane E.
Henney, M.D., Commissioner of FDA, Before the Committee on Government Reform, U.S. House of Repre-
sentatives, at 2 (Mar. 25, 1999), <www.fda.gov/ola/dietary.html>.
"
1See, e.g., Rochelle Sharpe, Staking Claims: One Effect ofA Law on Diet Supplements is Leaner Regu-
lation, WALL ST. J., Jan. 27, 1999, at 1. This describes one businessman's start-up company, that sells andros-
tenedione under claims that it is "safe," "proven," "FDA legal," that it "reverses male aging" and "burns fat,
builds muscle and boosts strength, energy and sex drive." Id. The seller states that he has no concerns about the
safety or efficiency of his product containing androstenedione, because he has "done research" consisting of his
personal experience with the product and "reading up on the substance over the Internet for a week." Id. He
recommends one 100 mg. tablet per day. In contrast, a medical doctor who has given patients androsteneione
limits his patients to one or two 100 mg. tablets per week, monitors the patients' reactions, and requires them to
undergo medical testing if they wish to increase their dosage. Doctors have concerns that the substance adversely
could affect the prostate gland or the heart. Id.
"
9National Public Radio: Dietary Supplements, (Morning Edition broadcast, Mar. 30, 1999) (visited
Apr. I, 1999) <www.npr.org/programs/moming/dietsupplements/html>.
39 See generally Legi-Slate, Alternative Medicine: America v Top 10 Herbal Remedies (visited Mar. 22,
1999) <www.legislate.com/Itpdir/diettab.htm> (reporting on the increase in sales of herbal products); Dana
Canedy, Real Medicine or Medicine Show? Growth of Herbal Remedy Sales Raises Issues About Value, N.Y.
TIMES, July 23, 1998, at DI.
6°National Public Radio: Dietary Supplements, supra note 58; see also text infra, accompanying notes
82-89 (discussing the availability of Cholestin®, a dietary supplement containing the same substance as is avail-
able in the prescription drug Mevacor@).
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under the broad definition of "dietary supplements," there are health care concerns
about use of these products by the public without physician supervision.
6
1
In addition, supplements that are not marketed as prescription drugs in other
countries or in the United States have had negative effects on consumers, raising the
question of whether the existing definition covers only products that do not require
premarket screening for safety. For example, Gamma-Butyrolactone, marketed as a
sleep aid and a body-building supplement, has caused symptoms similar to intoxica-
tion in at least one case and seizures in another.62 FDA asked manufacturers to pull
products containing this substance from their shelves after the products caused at
least fifty-five cases of serious illnesses and one death. 63 Other studies show reason for
concern about the safety of other widely promoted herbal remedies.'
FDA informed Congress that the number of reported adverse reactions to dietary
supplements is increasing. 65 News reports indicate that serious adverse reactions to
readily available supplements are a problem. 66 DSHEA's suggestion that the fact that a
substance was marketed, in some form, in the United States as a food or dietary supple-
ment before October 1994, gives sufficient evidence of a substance's safety is, in short,
becoming increasingly doubtful.
67
B. Consumer Use of Dietary Supplements: To Cure as Well as to
Promote Health
In response to claims made by promoters of these supplements, consumers take
supplements not only to "affect the structure and function of the body" or to promote
general well-being, but also to treat and prevent diseases. A recent study shows that
significant groups of the public believe that supplements can "generally help people
with ... illnesses. '6 Furthermore, anecdotal evidence suggests that some consumers
6! Particularly troublesome in light of these concerns is research indicating that up to 72% of patients
taking "unconventional treatments" do not inform their physicians. See Yitzhak Beigel et al., A Leading Ques-
tion, NEw ENG. J. MED., Sept. 17, 1998, at 827-30, n.4.
6 See Frank LoVecchio, D.O. et al., Butyrolactone-Induced Central Nervous System Depression AfterInges-
tion ofRenewTrient, a "Dietary Supplement, " NEW ENG. J. MED., Sept. 17, 1998, at 847-48 (describing case of 36-
year-old man stopped by police for driving erratically after ingesting 2 ounces of"RenewTrient" dietary supplement);
National Public Radio: Dietary Supplements, supra note 58 (describing case of woman who took a GBL sleep aid
and required hospitalization the following morning for seizures, vomiting, and loss of consciousness).63 See Harris, supra note 56.
64 See, e.g., Robert S. Dipaola et al., Clinical and Biologic Activity ofan Estrogenic Herbal Combination
(PC-SPES) in Prostate Cancer, NEW ENG. J. MED., Sept. 17, 1998, at 785-91 (finding that the "use of this un-
regulated mixture of herbs may confound the results of standard or experimental therapies and may produce
clinically significant adverse effects").
65 FDA Sees Dietary Supplement Adverse Event Reports Growing, F-D-C REP. ("The Tan Sheet"), Mar.
1, 1999, at 5. FDA noted that "[flor products for which premarket review programs do not exist, such as dietary
supplements and cosmetics, FDA needs information about the safety and usage patterns of such products after
they have been approved in order to develop appropriate responses." Id. "Dietary supplements are not subject to
a premarket safety review or approval by FDA," the agency said. "This means that post-market surveillance,
including monitoring of adverse effects associated with marketed products, is the cornerstone of FDA's ability to
meet its public health responsibilities for the safety of these products." Id.
'See, e.g., Across the USA: News from Every State, USA TODAY, Mar. 17, 1999, at 4A (reporting that increas-
ing numbers of young people are reporting to Maryland emergency rooms and poison control centers after ingesting
gamma hydroxy butyrate, an "easily available hallucinogenic drug"); Vignuolo, supra note 19, at 200 (discussing
news coverage of the supplement ephedra that, since 1993, has caused nearly 400 adverse events and 15 deaths).
67See21 U.S.C. §§ 321(ff), 350b.
68 National Public Radio/Kaiser Family Foundation/Kennedy School of Government Survey on Ameri-
cans and Dietary Supplements, at question 8 (1999) (visited Mar. 29, 1999), <www.npr.org> [hereinafter NPR
Poll]. Forty-nine percent of those surveyed believed that supplements could help them with the flu, 61% with a
cold, 35% with cancer, 16% with AIDS, 53% with arthritis, and 52% with depression. Id.
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are using supplements instead of conventional medicine prescribed by physicians to
treat diseases such as high blood pressure, high cholesterol, diabetes, and even can-
cer.69 Despite the lengthy legal debate about how the wording of various claims distin-
guishes a health claim (regulated under NLEA) from a drug claim (regulated by FDA)
from a DSHEA statement of nutritional support and well-being (regulated, if at all, by
the FTC to protect against fraudulent content),7 0 consumers often perceive claims made
by dietary supplement manufacturers as claims that the products will prevent and cure
illnesses.71
C. Purity and Consistency of Dietary Supplements
Finally, there are serious concerns about the purity of dietary supplements. For
example, one study of Asian patent medicines found that of 260 medicines available
in California retail health food or herbal stores, thirty-two percent contained "unde-
clared pharmaceuticals or heavy metals," twenty-three products had more than one
adulterant, twenty-four products contained amounts of lead of at least ten parts per
million, seven percent contained undeclared pharmaceuticals, and fourteen products
had labels declaring pharmaceutical ingredients. 72
Another report described two patients who reported to emergency rooms with
nausea, vomiting, lethargy, irregular heartbeats, chest pressure, shortness of breath,
and heart palpitations after taking dietary supplements (marketed for "internal cleans-
ing") that included herbs contaminated with digitalis lantana.73 Digitalis lantana is a
toxin containing cardiac glycosides, which are substances that block electrical im-
pulses to the heart and cause irregular heartbeat in otherwise healthy individuals.74 After
these cases were brought to the attention of FDA, manufacturers and distributors of
the contaminated herbs initiated thirteen voluntary recalls, eight firms received warn-
69 National Public Radio: Dietary Supplements, supra note 58 (interviewing consumer who, against the
advice of physicians, is using dietary supplements to treat high blood pressure, cholesterol, and borderline diabe-
tes); see also Max J. Coppes, M.D., Ph.D. et al., Alternative Therapiesfor the Treatment of Childhood Cancer,
NEw ENO. J. MED. Sept. 17, 1998, at 846-47 (discussing two child cancer patients whose parents opted to treat
them with herbal compounds, in one case Matol Biomune OSF Plus (alleged to "create a synergistic effect on the
immune system, resulting in the elevation of natural killer cell activity" and promoted as beneficial for the
treatment of a variety of cancers and other diseases), and shark cartilage in the other).
10 A statement by Robert McCaleb, a member of the Presidential Commission of Dietary Supplement
Labels, captures the confusing lines between these distinctions. Mr. McCaleb states that "[r]egardless of what the
consumer believes to be the health impact of a physiological effect of a substance, it is the wording of a claim that
determines the type of claim being made." Allison Wright, FDA s Position on Cholestin Is Misguided, Say
Industry Groups, FooD LABELING & NUTRITION NEWs, Jan. 15, 1998, at 8-10. Mr. McCaleb goes on to note that
"prevents heart disease" is a drug claim, while "may reduce the risk of heart disease" is an NLEA health claim,
and "reduces blood cholesterol" is a DSHEA statement of nutritional support. Id.
71 According to the NPR Poll, supra note 68, 64% of those surveyed believed that the phrase "supports or
boosts the immune system" means that the product will prevent one from getting sick, and 42% believe the same
statement indicates that the product will help one who is already sick get better. Id. at questions 9-10.
72 Richard J. Ko, Pharm. D., Ph.D., Adulterants in Asian Patent Medicines, NEw ENG. J. MED., Sept. 17,
1998, at 847; see also Yitzhak Beigel et al., supra note 61, at 827-30 (discussing the case of a 43-year-old man
hospitalized with unusual symptoms and eventually diagnosed with lead poisoning resulting from his intake of
an "Indian plants" herbal remedy, and noting that there have been several reports of lead intoxication from
Indian plants in patients with diabetes).
'3 Nancy R. Sligman, M.D., M.P.H, et al., Contamination ofiBotanicalDietary Supplements by Digitalis
Lantana, NEw ENG. J. MED., Sept. 17, 1998, at 806-11.
74 d. Generally, a glycoside is a "compound formed by replacing the hydroxyl (-OH) group of a sugar by
another group." BANrr1's MED. DICTnONARY 185 (rev. ed 1990) "Glycosides found in plants include some phar-
macologically important products (such as digitalis)." Id.
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ing letters from FDA, and FDA issued press releases and posted warnings on its
website, telling consumers to avoid these products.75
In addition, there are concerns about the consistency of dietary supplements, par-
ticularly herbal supplements. Ideally, consumers of botanical products could be confi-
dent that the herbal extract pill they are taking has a predictable chemical composi-
tion and a consistent amount of the active ingredient. Recent studies of supplements,
however, show that consistency varies drastically among widely available brands of
the same supplement. For example, St. John's Wort, the herbal remedy publicized for
its benefits in counteracting depression, recently was studied by the Good Housekeep-
ing Institute, the Milwaukee Journal Sentinel, and the Los Angeles Times. In the first
study, a comparison of six "widely available" St. John's Wort supplements found a
"startling lack of consistency" in the quantity of what are believed to be the active
ingredients of the herbal remedy.76 One manufacturer withdrew its St. John's Wort
product from retail pharmacies in Wisconsin after laboratory tests demonstrated that
the product contained only 5.3% of the quantity of active ingredient claimed on the
label.77 Moreover, laboratory tests conducted by the Los Angeles imes on ten brands
of St. John's Wort showed that three brands had "no more than about half the potency
listed on the label," and four more had "less than 90% of the indicated potency."7 Other
herbal products have been studied with similar results.7 9
VI. FDA ATTEMPTS TO REGULATE UNDER DSHEA
What steps is FDA taking to address these concerns? The following section briefly
discusses FDA's actions in recent years regarding the definition of dietary supple-
ments, the claims surrounding those supplements, and the purity and manufacturing
practices of the supplements.
A. Definition of Dietary Supplements
As discussed above, the definition of dietary supplements provided by DSHEA is
extremely broad. Section 201 (ff)(3)(A) of the FDCA explicitly provides that "dietary
supplement" includes an "article that is approved as a new drug," as long as that
"article" was marketed as a dietary supplement or a food prior to the drug
approval.8 0 This provision means that the same substances that are required to go
75 Sligman, supra note 73, at 807. Interestingly enough, the imported raw material that had been contami-
nated with digitalis lantana had been supplied and distributed in the U.S. for approximately two years before the
problem was brought to FDA's attention by alert physicians. Id. Authors of the New England Journal of Medi-
cine article theorized that the medical community, as well as consumers of dietary supplements, may be unaware
that they can and should report adverse events associated with dietary supplements to FDA, which has a program
(Meditate) specifically designed to investigate such complaints. Id. at 810.
Mike Schwartz, Health and Fitness: The Debate: Some rootfor herbs, others claim deception, PRESS-
ENTERPRISE (Riverside, Cal.), June 30, 1998, at D 1. The study found that the largest amount ofhypericin in the
manufacturers' recommended doses was 17 times the smallest, and the largest amount of pseudohypericin was
13 times the smallest. Id.
77 Joe Manning & John Fauber, Aurora Recalls Herbal Pill After Lab Test St. John s Wort Trouble Illus-
trates Industry s Pitfall, MILWAUKEE J. SENTINEL, Mar. 11, 1999, at 1, available in 1999 WL 7666562.
7 Terence Monmaney, Remedy's U.S. Sales Zoom, but Quality Control Lags; St. John's Wort: Regula-
tory Vacuum Leaves Doubt About Potency, Effects of Herb Used for Depression, L.A. TIMES, Aug. 31, 1998,
at 1, available in 1998 WL 18869834.
79See, e.g., National Public Radio: Medical: Domestic (Morning Edition broadcast, Oct. 2, 1997), avail-
able in 1997 WL 12823399 (discussing study of ginseng, which found that "of four national brands, two didn't
have ginseng at all, and two had ginseng but had been so damaged that it was essentially worthless").
-021 U.S.C. § 321(ff)(3)(A).
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through the lengthy and costly new drug application (NDA) process, as long as they
were previously available in some form in the U.S. food supply, can be sold as dietary
supplements as well as drugs.8
1. The Cholestin® Decision: Dietary Supplement or Drug?
This definition posed problems for FDA when Pharmanex began marketing a
dietary supplement called Cholestin®. Cholestin®, which is derived from red yeast
rice, has been touted for its ability to lower cholesterol. In fact, the red yeast rice in
Cholestin® is a natural source of lovastatin, 2 the active ingredient in a prescription
drug, Mevacor®. News coverage of Cholestin® stressed that it was as effective as, and
less expensive than, its prescription drug counterpart. 3 Cholestin® initially was mar-
keted with labeling "that flamboyantly said this is, in effect, the same as the prescrip-
tion drug Mevacor."' 4 After an administrative proceeding to determine the status of
this product, in May 1998 FDA declared that Cholestin® was an unapproved drug,
and issued a notice barring Pharmanex from importing red yeast rice. 5 In response,
Pharmanex brought an action for preliminary injunction and declaratory judgment
against FDA, and was successful in both. 6
FDA argued that because Cholestin® contains lovastatin, the active ingredient of
an FDA-approved prescription drug, Cholestin® is inherently a drug.87 Lovastatin, the
agency claimed, is an "article" that was approved as a new drug and that was not
available in the food supply before that approval. In effect, FDA's position depended
on the definition of the word "article," and a determination that "article" refers to the
lovastatin.88 The District Court of Utah rejected this position, finding instead that
11 Id. Articles that were not present in the food supply or against which FDA has issued regulations are not
"dietary supplements." 21 U.S.C. § 321 (ff)(3)(B).
82 Red yeast rice contains mevinolin, "a natural substance that FDA has determined is chemically indistin-
guishable from lovastatin." Pharmanex v. Shalala, 1999 WL 80950 *3 (D. Utah 1999).
13 See, e.g., Suzanne Leigh, Tests Show Dietary Supplement Lower Cholesterol; Rice Product Costs
$20-30 a Month vs. $120-300for Prescription Drug, FORT WORTH STAR-TELEGRAM, Jan. 30,1999, at 6 (noting
that "[t]ests on a product described as a dietary supplement have indicated that it is as effective as expensive
prescription drugs for lowering cholesterol").
" Peter B. Hutt, Edited Transcript ofRemarks of Peter Barton Hutt to NDMA Government Affairs Com-
mittee, Sept. 23, 1998, at 6. After FDA began its investigation of Cholestin®, Pharmanex modified its labeling
of the product, removing specific references to mevinolin or lovastatin and limiting its statements of nutritional
support to claims such as "promotes healthy cholesterol," "maintains healthy cholesterol," "reduces total choles-
terol," "inhibits production of cholesterol in the body," and "keeps cholesterol in healthy balance." Allison
Wright, Maker Implements Interim Cholestin Labeling and Marketing Policy FOOD LABELING & NUnuRTION
NEws, Jan. 8, 1998, at 5.
" Cholestin Maker Wins Injunction Against FDA Over Red Yeast Imports, ANDREWS PHARMACEUTICAL
LITIG. REP. 3, July 1998, available in WL 14 No.2 ANPHARLR 3; Cholestin Maker Seeks Preliminary Injunc-
tion Barring Reclassification, ANDIREWS PHARMACEUTICAL LITIG. REP. 3, June 1998, available in WL 14 No. 1
ANPHARLR 8.
"R Court Ruling on Cholestin is a Setbackfor FDA in Implementing DSHEA, FDA WEEK, June 19, 1998,
at I (noting the court's preliminary ruling that Cholestin® is a dietary supplement and not a drug); Pharmanex,
1999 WL 80950.
"FDA initially had taken the position that the claim that Cholestin® "lowers cholesterol" is a drug claim.
They abandoned that position in the administrative decision, however, deferring the claims issue to their April
1998 rulemaking on structure/function claims, discussed infra. Hutt, supra note 84, at 7.
88 FDA's interpretation was that:
the word "article" as used in the phrase "article approved as a new drug under section 355" in [21
U.S.C.] §321(ft)(3)(B) can refer to either a finished drug product or any of that drug product's
individual components, depending on the particular circumstances surrounding the manufacture and
marketing of the dietary supplement at issue.
Pharmanex, 1999 WL 80950, at *3.
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"article" refers not to the lovastatin, but to the finished drug product
Mevacor®. 9 Therefore, unless Cholestin ® includes the finished drug product Mevacor®,
or was approved as a new drug, it cannot be said that Cholestin® includes an "article
approved as a new drug" that was not present in the food supply before such approval.
This decision relied extensively on evidence of congressional intent found in a
Senate report explaining that "on occasion, a substance that is properly included as a
dietary ingredient in a dietary supplement (food) product may also function as an
active ingredient in a drug product."90 While it may appear doubtful that Congress
actually intended for all substances tested and approved as prescription drugs to be
available as dietary supplements, thus bypassing not only the new drug approval pro-
cess but also the step from prescription drug to over-the-counter (OTC) status, the
legislative history can be read to support such a view.9
Interestingly, the "official" legislative history accompanying DSHEA is less illu-
minating. It consists of a one-page "Statement of Agreement," noting that "no other
reports or statements [should] be considered as legislative history for the bill" and
giving no insight into Congress' intentions beyond those listed as legislative findings
in the first portion of the Act itself.92
The Cholestin® decision was a dramatic setback to FDA's ability to regulate dietary
supplements. This decision encourages manufacturers of dietary supplements to find
and market "natural" substances, which are the active ingredients in prescription drugs,
without going through the NDA process otherwise required. It is likely that such sub-
stances can be found, because many prescription drugs are derived from natural sub-
stances: digitalis is extracted from purple foxglove, morphine from poppy, and quinine
from cinchona bark.93 This interpretation essentially undercuts the entire NDA process.
Prescription drug manufacturers can be expected to be less likely to pursue clinical trials
and studies of medications derived from natural substances (or chemical substances that
are indistinguishable from a natural substance), for fear that a dietary supplement could
market the same product with less cost and less regulation.94
This situation is harmful. The argument that "natural" substances are somehow
safer than prescription drugs is undercut by the fact that many prescription drugs are
derived from natural substances, as explained above, and yet are classified as pre-
scription drugs. One of the reasons for strict regulation of prescription medications is
the rigorous testing needed to ensure safety and efficacy. Another reason for a product
11 id. at *7.
"'Id. at *2.
9' Indeed, James Rippe, Director of the Center for Clinical and Lifestyle Research (and co-chairman of the
Pharmanex medical advisory board) argues that "[t]he Cholestin issue offers the clearest example that I have
seen to date of accomplishing precisely what DSHEA intended, namely to encourage companies to seek natural
products which have been in use for extended periods of time which could potentially result in health benefits."
Allison Wright, supra note 70, at 9-10.
9121994 U.S.C.C.A.N. § 3523.
13 Marcia Angell, M.D. & Jerome P. Kassirer, M.D., Alternative Medicine - The Risks of Untested and
Unregulated Remedies, NEW ENG. J. MED., Sept. 17, 1999, at 839-41. Dr. Kessler, former Commissioner of
FDA, noted in 1993 that approximately one-half of all drugs are derived from plants. See Legislative Issues
Related to the Regulation of Dietary Supplements: Hearing Before the Senate Labor & Human Resources
Committee, 103d Cong., I st Sess., at 21 (statement of Dr. Kessler) (1994).
Indeed, some of the biggest pharmaceutical companies are planning to sell their own herbal products, a
possibility that concerns William B. Schultz, former FDA Deputy Commissioner for Policy. "If companies that
would have tested their products and sold them as drugs are now going to not test them and sell them as dietary
supplements, then we have lost information about the safety and efficacy of those products," Mr. Schultz notes.
Sheryl Gay Stolberg, Drug Regulators Make Push to Rein In Herbal Remedies, N.Y. TIMES, June 10, 1998, at
A l; In the Wake of the Cholestin® Decision, Merck is Considering Asking the FDAfor Permission to Switch
Mevacorg to an OTC Product, FOOD LABELING NEWS, Apr. 14, 1999, at 1064-6329.
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to be regulated as a prescription medication (and not as a dietary supplement or an
OTC product) is to provide an element of medical supervision. Many substances that
have beneficial effects also have potentially negative side effects. In addition, some
medications that are beneficial to individuals with a particular problem can be harm-
ful to those that do not have the condition. For example, digitalin can be used to
stimulate heart activity in individuals with congestive heart failure, a condition in
which the heart is unable to sustain an adequate output to meet the body's needs.95 If a
person with a normal heart takes digitalis, however, it can result in irregular heart-
beats and other adverse effects (including death).9 6
Mevacor® itself provides an example of why physician supervision is needed.
While lovastatin does lower cholesterol with relatively few side effects, it is contrain-
dicated for women of childbearing age or pregnant women, because it has the poten-
tial to cause damage to the fetus.97 According to the Physicians 'Desk Reference (PDR)
entry on Mevacor®/lovastatin:
... cholesterol and other products of the cholesterol biosynthesis pathway
are essential components for fetal development.... Because of the ability of
inhibits of MHG-CoA reductase such as MEVACOR to decrease the synthe-
sis of cholesterol and possibly other products of the cholesterol biosynthesis
pathway, MEVACOR is contraindicated during pregnancy and in nursing
mothers. MEVACOR should be administered to women of childbearing age
only when such patients are highly unlikely to conceive.9"
In addition, lovastatin can cause liver dysfunction in certain patients, and it is
recommended that physicians carefully monitor patients who are taking both lovastatin
and immunosuppressive drugs or lipid-lowering doses of nicotinic acid.99 Because
patients taking herbal remedies often assume they are safe and fail to inform their
physician that they are ingesting these substances, the necessary physician monitor-
ing is unlikely to occur in patients taking Cholestin®, even though it seems virtually
certain that the same risks exist.1"'
FDA filed an appeal of the Pharmanex decision, and the issues were briefed in
July 1999."' In the interim, the agency may hope that other district courts will not
follow the lead of the Utah court. If FDA's efforts to push their interpretation of di-
etary supplements is unsuccessful, however, there are relatively few regulatory op-
tions left open for the agency to address the safety problems posed. An examination of
potential regulatory options available to FDA, using Cholestin® as an example and
focusing on the potential for this product to harm a fetus should be illustrative.
95 KURT J. ISSELBACHER ET AL., HARRISON'S PRINCIPLES OF INTERNAL MEDICINE 1005-06 (13th ed. 1994) (dis-
cussing control of heart failure with cardiac digitalis glycosides).
" See supra notes 72-75, and accompanying text. Adverse effects also can occur if an congestive heart
failure patient takes too much digitalis, or if the patient has inadequate potassium levels in her blood.
9 PHYSICIANS' DESK REFERENCE 1834-38 (47th ed. 1993).
9 I1d. at 1836 (emphasis in original).
99Id.
10o Cholestin® is not the only herbal remedy that can create risks related to fertility and pregnancy. A recent
study found that St John's Wort, echinacea, and ginkgo biloba all had negative effects on eggs or sperm or both,
and could interfere with conception or a healthy pregnancy. Jane E. Brody, HerbalRemedies Tied to Pregnancy
Risks, N.Y. TIMES, Mar. 9, 1999, at F7. This article noted that "[d]espite the widespread belief, often fostered by
advertising copy, that herbal preparations are "natural" and "drug-free," those that have drug-like effects in the
body do in fact contain potent chemicals that act like drugs." Id.
I FDA Tells Appeals Court that Cholestin is not a Dietary Supplement, FOOD LABELING NEWS, July 28,
1999, at 1064-6329.
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One possible regulatory option is to argue that the product is adulterated under
section 402(f) of the FDCA, which provides that food is "adulterated" if it is a dietary
supplement or contains a dietary ingredient that:
(A) presents a significant or unreasonable risk of illness or injury under -
(i) conditions of use recommended or suggested in labeling, or
(ii) if no conditions of use are suggested or recommended in the label-
ing, under ordinary conditions of use.10 2
If the labeling of Cholestin® does not include a warning that pregnant women
should not ingest the product, it is possible to argue that the product presents a "sig-
nificant risk" that the fetus will suffer illness or injury. If it wished to make this
argument, FDA would have to prove several different points. First, it would have to
show that Cholestin® does present a significant risk of injury to the fetus. The scien-
tific evidence on this point, while convincing enough to result in a contraindication
warning for the prescription drug containing the same active ingredient, may not be
sufficient to prove this for the dietary supplement. The PDR entry on MevacorO notes
that "lovastatin has been shown to produce skeletal malformations at plasma levels 40
times the human exposure (for mouse fetus) and 80 times the human exposure (for rat
fetus)," 3 and that "reports of congenital anomalies have been received following in-
trauterine exposure to HMG-CoA reductase inhibitors."'1°4 A review of 100 pregnant
women exposed to Mevacor® or a similar drug, however, showed that "the incidences
of congenital anomalies, spontaneous abortions and fetal deaths/stillbirths did not
exceed what would be expected in the general population."'' 5 Because safety has not
been established, there is a risk of damage to the fetus, and there is "no apparent
benefit" to treating pregnant women with lovastatin, the PDR recommends that "treat-
ment should be immediately discontinued as soon as pregnancy is recognized."'0 6 It is
not clear, however, whether this evidence would be sufficient to clearly show that this
presents a "significant" risk of injury to the fetus.
This point draws attention yet again to the distinction between prescription drugs
and dietary supplements. While the same evidence exists for the prescription drug
form of lovastatin and the dietary supplement form of lovastatin, the existing regula-
tory structure ensures that one will be withheld from pregnant women while the other
virtually will be unregulated.0 7
Even if FDA were able to argue successfully that the evidence shows a significant
risk to the fetus, it would face arguments that the language was intended to protect the
individual taking the supplement (i.e., the pregnant woman, and not her fetus). Addi-
tionally, FDA would have to show that the conditions of use recommended in the
labeling included pregnant woman.' If there were no conditions of use listed, to pre-
1221 U.S.C. § 342(f)(1)(A).
103 PHYSICIANS' DESK REFERENCE, supra note 97, at 1838.
104 Id.
105 Id.
106 Id.
107 While the PDR is not per se evidence of the existing medical standard, it seems extremely unlikely that
a physician would prescribe a drug in a case where there is potential risk and no apparent benefit. A woman
unaware of the studies showing potential risk, and reading only of the cholesterol-lowering benefits of Cholestin®,
however, might decide to take the dietary supplement while pregnant.
101 Based on the plain meaning of the rule, one could argu that, if the labeling language was "take one per
day" and included no warning (such as "pregnant women should not take this product"), the conditions of use
requirement would be met.
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vail FDA would need to make the argument that "ordinary conditions of use" are such
that pregnant women would consume sufficient amounts of the supplement to produce
harm to the fetus.
Another regulatory option for FDA is to pass a regulation under the "misbranding"
sections of the FDCA requiring that "information relating to" additional nutrients be
included on the label. Food is "misbranded" under section 403(q)(1)(E) of the FDCA if
its labeling does not comply with any regulation passed by FDA."0 9 Section 403(q) of the
FDCA allows FDA to pass regulations requiring any "other nutrient" be listed on the
label of a food "if the Secretary determines that such information will assist consumers
in maintaining healthy dietary practices."'"FDA also can require that "information
relating to such additional nutrient" II be included. Under those provisions, it is plau-
sible that FDA could force Pharmanex to include information about lovastatin, includ-
ing a pregnancy warning, on the label of Cholestin®, or to provide a package insert
similar to those included with OTC drugs. The basis for this requirement would be that
the pregnancy warning or insert explanation would be "information relating" to an
additional nutrient in the food." 2 The additional nutrient (lovastatin) arguably could be
required to be listed on the label once FDA determined that the listing of it would "assist
consumers in maintaining healthy dietary practices.""' 3
2. Benecol. • Dietary Supplement or Food?
Cholestin® is not the only dietary supplement that raises troubling definitional
questions for FDA. McNeil Consumer Healthcare has announced its desire to market
Benecol®, a margarine-like product made in Finland purported to lower cholesterol.
Benecol®, unlike other margarine spreads, contains stanol ester, a derivative from
wood and other plants that has been shown to prevent cholesterol from entering the
bloodstream."1 4 If Benecol® is a dietary supplement, as the company claims, then FDA
has limited regulatory authority. FDA, however, has taken the position that Benecol®
is a food and that FDA has authority to determine the safety of stanol ester (under its
food additives provisions) before allowing Benecol® to be marketed." 5
B. Claims for Dietary Supplements: What Can Manufacturers Say?
The arguments over definition of supplements can be seen as the threshold argu-
ment of what claims can be put on particular products. The issues of definition and
claims are intertwined: defining a product as a dietary supplement is important only
because it allows various claims to be made without strict regulation, and the claims
that are placed on a product determine whether it is a food/dietary supplement or a
drug. Under DSHEA, dietary supplements can claim to affect the "structure or func-
tion" of the body, but cannot claim to cure, prevent, or treat any disease." 6 This system
,o" 21 U.S.C. § 343(q)(I)(E).
10Id.
I d. § 343(q)(2)(A).
12 See id.
"13 See id. § 343(q)(1)(E).
"' National Public Radio: Business: Domestic (Morning Edition broadcast, Nov. 4 1998), available in
1998 WL 3309258; Harris, supra note 56, at 7.
"' See National Public Radio: Business: Domestic, supra note 114; Harris, supra note 56, at 7; see also
Timothy Gower, Rating the Cholesterol Busters, HEALTH, Nov. I, 1998, at 120, available in 1998 WL 14273576.
For those who "can't wait" to get Benecol®, the compounds in it, phytosterol, are available in capsule form in
health food stores and through mail-order firms. Id.
"'
6 See supra notes 50-52, and accompanying text.
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allows manufacturers of dietary supplements to hint that a product will help a disease
without actually saying so (e.g., "lowers cholesterol" is reasonably understood by con-
sumers to mean that the product treats the illness of high cholesterol).
1. FDA Regulation of Claims and the Pearson Decision
In April 1998, FDA proposed regulations on statements made for dietary supple-
ments that were intended to give guidance on what types of statements were permis-
sible structure/function claims and what types of statements were impermissible drug
claims."7 In part, that proposed rule defined "disease" as "any deviation from, impair-
ment of, or interruption of the normal structure or function of any part, organ, or
system (or combination thereof) of the body that is manifested by a characteristic set
of one or more signs or symptoms."" ' This proposed definition has created great
controversy." 9 Commentators have noted that "[t]here is no such thing as a normal
body,"'l2 and because "[v]irtually anything is a deviation from a normal body," 2' a
literal interpretation of this definition would effectively mean that "there [is] no such
thing as a structure/function claim" and that all claims are disease (drug) claims.'22
FDA Commissioner Dr. Jane Henney declared that she has not determined yet
whether she agrees with this definition of disease, but notes the importance of settling
"this key issue of 'disease,' for it is that definition that will guide the setting of the
boundaries."'23 The controversy over the structure/function proposed rule essentially
is a difference of opinion between those who feel that structure/function claims, which
imply disease prevention and lead to consumers taking dietary supplements to prevent
or cure disease are harmful, 2 4 and those who feel that "while some people might infer
a disease-related claim from certain product labels, it is critical to permit helpful
structure/function claims made in good faith."'25
11 Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the
Structure or Function of the Body, 63 Fed. Reg. 23,623 (Apr. 29, 1998) (to be codified at 21 C.F.R. pt. 101).
Id. at 23,625 (discussing proposed 21 C.F.R. § 101.93(g)(I)).
19 Between April 1998 and March 1999 FDA received more than 100,000 comments on the proposed
rule, of which approximately 90% were critical. David Brown, New FDA Commissioner Enters War Over
Words, WAStI. POST, Mar. 26, 1999, at A3 I.
120 Hutt, supra note 84, at 4-5.
121 Id.
'
22 Id. 1. Scott Bass, an attorney for supplement manufacturers, argues that "[tihe way 'disease claim' is
defined can make almost any health claim illegal." See Brown, supra note 119, at A3 I. At a March 25, 1999
hearing held by the U.S. House of Representatives Government Reform Committee, several of the industry
representatives suggested that FDA should abandon its proposed rule because the rule would cover too many
structure/function claims. See, e.g., !. Scott Bass, Congressional Testimony off. Scott Bass Before the Commit-
tee on Government Reform, Mar. 25, 1999, available in 1999 WL 8082624; R. William Soller, Testimony of
R. William Soller for the Consumer Healthcare Products Association Before the House Committee on Gov-
ernment Reform, Mar. 25, 1999, available in 1999 WL 8086159; Annette Dickinson, Testimony of Annette
Dickinson, Ph.D., for the Scientific and Regulatory Affairs Council for Responsible Nutrition Before the
House Committee on Government Reform, Mar. 25, 1999, available in 1999 WL 8086158.
2 Brown, supra note 119, at A3 I.
124 See, e.g., Margaret Gilhooley, Testimony of Prof Margaret Gilhooley of Seton Hall Law School
Before the House Committee on Government Reform on Dietary Supplements, Mar. 25, 1999, available in
1999 WL 8086265. Prof. Gilhooley argues that the proposed FDA rules are too lenient. When a claim "relates
to a matter beyond the ability of the consumer to assess from their own experience," she argues, there is great
potential to mislead. Id. She argues for the position that "[p]roducts can be sold simply as dietary supplements,
but when they go beyond that to make a structure and function claim, the statement should relate to the role of the
dietary ingredient in the diet in achieving effects like those associated with the effects of foods.... For example,
a supplement might claim that it provides energy, has a wake-up effect like coffee or a calming effect like tea." Id.
121. Scott Bass, supra note 122. Mr. Bass argues that even "[i]f some people think that 'maintaining a
good circulatory system' is an implied heart attack-prevention claim, that should not in itself make a structure/
function claim illegal." Id.
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The fact that the proposed rule accepts as non-drug claims statements such as
"supports the immune system," "reduces stress and frustration," "helps maintain car-
diovascular function," "improves absent-mindedness " "promotes relaxation," and
"helps maintain regularity," shows how drastically the regulatory landscape has changed
in recent years. 2 6 FDA currently faces the virtually impossible task of finding a rule
that will satisfy both sides of this debate; while there are many industry representa-
tives who oppose the proposed rule as overly stringent, several consumer groups feel
that the rule does not go far enough.'27
FDA faces opposition to its restrictions on claims not only from industry and
congressional sources, but also from the courts. A decision reached early in 1999
struck down FDA's efforts to restrict health claims on foods and dietary supplements
under the NLEA, finding that First Amendment freedoms require the agency to be
particularly careful in restricting manufacturers' ability to make supportable state-
ments on their products' labels. In Pearson v. Shalala,28 the D.C. Circuit Court re-
viewed a challenge by the American Preventive Medical Association and other appel-
lants to FDA's final regulations promulgated under the NLEA. 2 9Those regulations,
which provide that a health claim can be made for either a food or a dietary supple-
ment only if, based on the totality of publicly available scientific evidence, FDA deter-
mines that there is "significant scientific agreement" that the claim is supported by
experts.' 3 Using that standard, FDA has evaluated proposed health claims put for-
ward by manufacturers of dietary supplements, including those in Pearson.3' FDA
rejected these claims on the basis that the scientific evidence was inconclusive.'
The court found that FDA's restrictions on commercial speech impermissible vio-
lated the First Amendment because the agency did not articulate a sufficient govern-
ment interest in restricting the speech. Instead, the court found that the government's
interest could be met by requiring a disclaimer under the claim, such as "[t]he evi-
See 63 Fed. Reg. at 23,523; Hutt, supra note 84, at 6. Hutt notes that the above claims are "claims that
five years ago would have gotten you into jail" and states that "[w]e have seen a revolution, which the dietary
supplement industry does not fully realize." Id.
127 See, e.g., Justice Asks Court to Rehear Landmark Nutrition Labeling Case, FDA WEEK, Mar. 26,
1999, at 4; see Gilhooley, supra note 124.
128 164 F.3d 650 (D.C. Cir. 1999).
29 One should be clear that "health claims" are separate from "structure/function" claims. Under the
FDCA, as amended by DSHEA, both foods and dietary supplements can make structure/function claims without
being classified as a "drug." See 21 U.S.C. § 321 (g)(l)(C) (defining "drug" as a article "other than food" which
is "intended to affect the structure or any function of the body of man or other animals"); 21 U.S.C. § 343(r)(5)(D)
(providing that a claim governed by § 343(r)(1 )(B) (i.e., a statement which "characterizes the relationship of any
nutrient [required by statute or FDA regulation to appear in the product's labeling] to a disease or a health-
related condition") "shall be subject to a procedure the standard, respecting the validity of such claim, estab-
lished by regulation of the Secretary"); 21 U.S.C. § 343(r)(6) (clarifying that a statement governed by §
343(r)(1)(B) may be made for a dietary supplement product if the statement "describes the role of a nutrient or
dietary ingredient intended to affect the structure or function in humans... or describes general well-being from
consumption of a nutrient or dietary ingredient").
130 Food Labeling Regulation, Amendment; Food Regulation Uniform Compliance Date; and New Di-
etary Ingredient Premarket Notification; Final Rules, 21 C.F.R. § 101.14(c).
131 Those claims include "consumption of antioxidant vitamins may reduce the risk of certain kinds of
cancers," "consumption of fiber may reduce the risk of colorectal cancer," "consumption of omega-3 fatty acids
may reduce the risk of coronary heart disease," and ".8 mg of folic acid in a dietary supplement is more effective
in reducing the risk of neural tube defects than a lower amount in foods in common form." Pearson, 164 F.3d at
652.
112 Id. at 654. FDA has approved only two health claims for dietary supplements: one supporting the link
between calcium and osteoporosis, 21 C.F.R. § 101.72(c)(2)(ii)(C), and one supporting the link between folate
and neural tube defects, 21 C.F.R. § 101.79(c)(2)(ii)(B). In contrast, several health claims have been approved
for foods, including one supporting the link between fiber and cancer. 21 C.F.R. § 101.76.
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dence is inconclusive [on this claim]." '133 Furthermore, the court found that the stan-
dard "significant scientific agreement" was an insufficient explanation under the re-
quirement that an agency not engage in arbitrary and capricious action.'34
While FDA is troubled by the implications of this ruling, further litigation of the
case has been discouraged by some members of Congress. In a letter to the FDA
Commissioner, a group of House Republicans requested "that the FDA spare the tax-
payers the cost of further legal proceedings" 3 and instead simply approve the claims
at issue in the case. Although FDA rejected this advice and asked for a rehearing of
the case, the D.C. Court refused.'36
FDA is taking steps to maintain its ability to regulate claims for dietary supple-
ments. Despite congressional opposition, FDA has persuaded the Department of Jus-
tice (DOJ) to seek a rehearing of the Pearson case.'The DOJ has requested that
either the original three-judge panel, or an en banc panel, rehear the case, arguing
that the ruling depended on "a misreading of Supreme Court commercial speech dis-
claimer precedents, none of which involved claims bearing on public health."'38 Fur-
thermore, the DOJ argued that the decision "effectively deprives FDA of the well-
settled power to define and apply regulatory provisions on a case-by-case basis."' 39 FDA
and the DOJ argue that if the decision stands, and dietary supplement manufacturers
are allowed to label their products with sweeping health claims as long as they include
a disclaimer, consumers will be unable to distinguish legitimate health claims from
ones that are less well-founded. 1
4
1
While FDA waits to see whether the D.C. Circuit will reconsider its position on
NLEA health claims, it also is considering the new rule on structure/function claims
for dietary supplements, discussed above. As Commissioner Henney considers com-
ments on the proposed rule, she also is considering establishing a panel, or a separate
committee within FDA that would review dietary supplement labeling claims.141 FDA
is planning to study consumer understanding of structure/function claims, focusing
on whether consumers are able to distinguish structure/function claims from drug
claims and whether consumers view dietary supplements (particularly botanicals) as
more or less risky than OTC drugs. 142 In addition to FDA's planned studies, other
organizations have encouraged Congress to allocate funds to study dietary supple-
ments. 1
43
FDA also has promulgated rules (first published in 1997 and effective as of March
1999) that require supplement manufacturers to print complete information on the
131 164 F.3d at 658.
134 Id. at 660 (citing 5 U.S.C. § 706(2)(A) (1994)).
"I' FDA "Further Litigation" of Pearson v. Shalala Discouraged by House GOPs, F-D-C REP. ("The
Tan Sheet"), Mar. 1, 1999, at 3.
.36 172 F.3d 72 (D.C. Cir. 1999).
... Justice Asks Court to Rehear Landmark Nutrition Labeling Case, FDA WEEK, Mar. 26, 1999, at 22.
1
38 Id.
139 Id.
4' "Having lost confidence in all claims, consumers would be less likely to adopt healthier dietary prac-
tices, ultimately increasing their risk of disease and preventable death," argued the Department of Justice in its
petition for rehearing. Id.
FDA Considers Setting Up Panel to Review Dietary Supplement Claims, FDA WEEK, Mar. 26, 1999, at 1.
FDA to Study Consumer Perception of Structure/Function Claims, FDA WEEK, Mar. 12, 1999, at 1.
"4' The National Institutes of Health requested that its budget for fiscal year 2000 include $50.2 million to
fund research on dietary supplements and alternative medicine. NIH Officials Brief Congressional Panel on
White House Request for $50.2 Million for Alternative Medicine Research, FooD CHEMICAL NEWS, Mar. 15,
1999, available in 1999 WL 9625453. This money would be used by the National Center for Complementary
and Alternative Medicine. One of the Center's first priorities is to study the efficacy of gingko biloba as a treat-
ment for dementia. Id.
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labels of their products.' The "Supplement Facts" panel must list: suggested serving
size, information on nutrients "present in significant levels;" the percent Daily Value
(of the Recommended Daily Allowance) where applicable, and "all other dietary in-
gredients present in the product."' 45
2. The FTC's Role in Regulating Claims
Consumers concerned about misleading or untruthful information about dietary
supplements may be comforted partly by the role of the FTC in regulating dietary
supplement advertising. The FTC has the authority to prevent companies from mak-
ing false and unsubstantiated statements about their products in advertisements, and
recently issued advertising guidelines intended to prevent false or misleading claims
about dietary supplements. 46 Presumably, at least the more egregious dietary supple-
ment claims are caught by the FTC's watchful eye. For example, the FTC recently
brought an action against Rose Creek Health Products, maker of "Vitamin
0.""14 "Vitamin 0," according to its advertising, addresses the problem of "oxygen
deficiency" by allowing oxygen molecules to be absorbed through the gastrointestinal
system upon oral administration of the product.'48 The FTC filed a complaint against
the company in U.S. District Court for the Eastern District of Washington on March
11, 1999.'49 Then in April, U.S. District Court Judge Edward Shea granted FDA's
request for a preliminary injunction limiting how Rose Creek could market "Vitamin
0." The FTC has taken similar actions in the past against dietary supplement manu-
facturers who make unfounded claims. 5 '
The FTC's jurisdiction is limited. The FTC regulates product advertising and
ensures the advertising is "truthful and not misleading" and that any statement made
has "adequate" substantiation of its truth.'5' The FTC, however, does not address safety
issues such as whether the manufacturer has provided adequate information about the
product's health risks, nor can the FTC (or, under current law, FDA) force a manufac-
turer to test a product to ensure that it is safe at the recommended dose and under the
recommended conditions.
3. Purity and Consistency
FDA is attempting to grapple with the purity and consistency problems associ-
ated with dietary supplements by proposing good manufacturing practices (GMPs)
I" U.S. Department of Health and Human Services, Dietary Supplements Now Labeled with More Infor-
mation, Mar. 23, 1999 (press release), (visited Nov. 18, 1999) <www.fda.gov/bbs/topics/NEWS/
NEW00678.html>. Food Labeling: Nutrition Labeling of Dietary Supplements on a "Per Day " Basis, 64
Fed. Reg. 1765 (codified at 21 C.F.R. pt. 101).
1
45 Id.
146 See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry, (1998)
(visited Nov. 18, 1998), <www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
"I U.S. FTC: FTC Charges Marketer of" Vitamin 0 " With Making False Health Claims, M2 PRESSWIRE,
Mar. 16, 1999, available in 1999 WL 140641239.
" "Mighty 'Vitamin 0', "BIo/TEcH NEwS (1998). This publication, touting "Inside Information" on the
product was mailed out to potential consumers. Testimonials in the advertising materials suggest that the product
effectively treats cancer, and will help breathing problems, headaches, infections, colds, and the flu.
"4 According to independent laboratory analysis, however, the product is nothing more than salt water.
Claire Martin, The 0 Hype "Vitamin 0 "ElixerJust Salt Water by Analysis, DENVER POST, Apr. 13, 1999, at El;
U.S. FTC supra note 146; Mike Roarke, RulingHasn ?Killed Vitamin 0 Sales, SPOKANE SPOKESMAN-REV., Apr.
30, 1999, at A16.
'50 For example, in 1998, the FTC forced New Vision International, Inc. to stop making claims that its
supplement could cure conditions such as Attention Deficit Disorder. The supplement, called "God's Cocktail,"
contained a mixture of minerals, anti-oxidants, and alfalfa sprouts. Harris, supra note 56, at 5.
151 Id.
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and developing an adverse events reporting system. DSHEA provided explicit author-
ity for FDA to create GMPs, and FDA published an Amended Notice of Proposed
Rulemaking (ANPR) in February 1997. 1 The ANPR set out the dietary supplement
industry's proposed GMPs and requested comments on that submission and on the
need for and ways to develop acceptable GMPs. Over two years have passed since the
comment deadline for this ANPR, and it seems that FDA will soon propose a GMP
rule for dietary supplements.'53
FDA also has developed programs through which consumers can report their
experiences of any adverse effects from dietary supplements. FDA's web page cites
several ways a consumer can report "a problem or illness caused by a Dietary Supple-
ment."' 54 Health professionals are encouraged to monitor and report adverse events
and product problems through FDA's "meditate" program.'55 In 1998, reports of ill
effects stemming from dietary supplements, compiled by FDA's Office of Special Nu-
tritional Adverse Event Reporting System, were placed on the website, providing con-
sumers greater access to information about potentially problematic products, but also
opening FDA to criticism that it has adopted a "guilty until proven innocent" stan-
dard for dietary supplement manufacturers. 56
VII. CONCLUSION AND RECOMMENDATIONS
FDA is attempting to effectively and fairly regulate dietary supplements. The
current congressional climate, however, is skeptical of FDA regulation. As noted above,
members of Congress have discouraged FDA from further pursuing appeals of ad-
verse court rulings, while other members are critical of FDA's proposed rule on struc-
ture/function claims.' In addition, legislative proposals offered in the 106th Con-
gress would ease governmental regulation and oversight of dietary supplements, while
expanding patient access to these products. One such proposal would ensure that
Medicare and Medicaid would cover payments for dietary supplements. 5
This legislative climate of skepticism of any increased regulation continues de-
spite evidence that the public would prefer greater regulation of dietary supplements
and more government involvement in the study of whether such products are safe and
effective. A recent study performed by National Public Radio, the Kaiser Foundation,
and the Kennedy School of Government suggests that many consumers feel there is
insufficient regulation of the safety and purity of supplements. 5 9 Many consumers
"1 108 Stat. 4325,4331 (DSHEA § 9) (adding 21 U.S.C. § 342(g)). Current Good Manufacturing Prac-
tice in Manufacturing, Packing, or Holding Dietary Supplements, 62 Fed. Reg. 5699 (Feb. 6, 1997).
'13 See Henney, supra note 56, at 3-4.
'14 See Food & Drug Admin., Center for Food Safety and Applied Nutrition, Overview ofDietary Supple-
ments (visited Mar. 24, 1999) <vm.cfsan.fda.gov/--dms/ds-oview.html>.
"I See, e.g., Food & Drug Admin., Meditate: The FDA Medical Products Reporting Program (visited
Apr. 19, 1999) <www.fda.gov/medwatch>.
36 See Annette Dickinson, supra note 122. Dr. Dickinson notes that "a company can find itself in the
position of having its company name and brand associated with a serious adverse event posted on the Web
without having any prior warning... [and] the background information on the case is unlikely to be available
under FOIA [the Freedom of Information Act], because FDA does not have adequate staff to purge personal care
information not releasable [sic] under FOIA." Id. She further notes that because of minimal FDA resources, the
agency has limited ability to properly investigate and evaluate complaints. Id.
"' At the March 25, 1999 congressional hearing, Government Affairs Committee Chairman Dan Burton
(R-IN) noted that "the proposed rule does not comply with the legislation." FDA Considers Setting up Panel to
Review Dietary Supplement Claims, FDA WEEK, Mar. 26,1999, at 4.
.. Harris, supra note 56.
' NPR Poll, supra note 68, at question 15. Of those polled, 59% felt that there was "not as much [regu-
lation] as there should be" to ensure that supplements "don't harm people who use them," and 60% felt that there
continued
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also want more government regulation to "make sure that health claims made in ad-
vertisements for these supplements are true."1
61
The lack of laws that would allow consumers to distinguish safe and effective
supplements from those that are benign but useless or harmful is disappointing, espe-
cially in light of the fact that many of the alternative medicines, including supplement
usage, show great potential for helping both minor and major ailments.' 6 1 As long as
the effective products are sold alongside (and often with labels identical to) useless or
harmful products, and as long as the available information includes only "studies"
conducted by those with a financial interest in the product, neither consumers nor
medical professionals, can be confident in the use of most supplements. Instead of
encouraging health care professionals to promote the use of these potentially useful
supplements, the unscientific and lax approach to regulating the supplements is an-
tagonizing and alienating such professionals and creating a break-down of communi-
cation between doctor and patient. While there is some reliable information available
about the safety and efficiency of various dietary supplements, the vast majority of
consumers interested in using such supplements appear to receive their information
from "product labels, health-food store salespeople, or friends."'
62
FDA is doing what it can to ensure the safety, if not the effectiveness, of supple-
ment products, but when the laws require them to act only when they have informa-
tion that a supplement actually is dangerous (rather than testing whether it is danger-
ous before allowing consumers to take it), there only is so much the agency can do.
Given the current climate, it is unlikely that the situation will change greatly until
there is a public outcry for Congress to adjust the laws. And it is unlikely that a public
outcry will occur absent some catastrophic adverse reaction to a supplement or other
major event.'63
What could be done to ameliorate the situation? A good solution would work to
ensure safety and efficacy of dietary supplements, and also ensure the availability of
helpful products without the long delay or price increases that seem likely to accom-
pany premarket screening. This paper offers one compromise solution. Let all manu-
facturers of dietary supplements pay a small tax - some minor percentage of their
profits - to finance an FDA report which will be available publicly and offered to
was "not as much [regulation] as there should be" to ensure that "these supplements are pure and their dosages
are consistent." Id. 24% and 23%, respectively, responded that the current regulations were the "right amount"
of regulation, and 7% and 6%, respectively, felt that there was currently "too much regulation." Id.
11 Id., at question 15-c.
61 For example, a recent Journal of the American Medical Association edition devoted to alternative
medicine published studies showing: that "moxibustion (stimulation of an acupuncture point by heat generated
from burning a specific herb) is helpful for correction of breech presentation in late pregnancy," that a "Chinese
herbal medicine formulation improves symptoms of irritable bowel syndrome"; and that saw palmetto extracts
"improve urologic symptoms in patients with benign prostatic hyperplasia." Francesco Cardini, M.D. & Huang
Weixin, M.D., Moxibustionfor Correction of Breech Presentation, JAMA, Nov. 11, 1998, at 1580; Alan
Bensoussan, M.Sc. et al., Treatment of Irritable Bowel Syndrome with Chinese Herbal Medicine: A Random-
ized Controlled Trial, JAMA, Nov. 11, 1998, at 1585; Timothy J. Wilt, M.D., M.P.H. et al., Saw Palmetto
Extractsfor Treatment of Benign Prostatic Hyperplasia, JAMA, Nov. 11, 1998, at 1604.
62 Kathleen Doheny, The RoadLess Traveled, SHAPE, May 1999, at 55. Medical Economics, the company
responsible for publishing the well-known Physicians 'Desk Reference, recently published THE PHYSICIANS'
DESK REFERENCE FOR HERBAL MEDICINES (1998), which offers information on more than 600 herbs. This publica-
tion relies in large part on information from the German Regulatory Authority's Commission E, the agency in
Germany responsible for safeguarding herbal medicine, and on the results of an international literature review.
'63 "People drink their herbal tea with ginseng or whatever, and they think 'what's the harm with nutritional
supplements like this? Well, in large part, we don't know," says Linda Golodner, President of the National
Consumers League. Ms. Golodner adds that "[w]e don't want consumers to be guinea pigs." Harris, supra note
56. At the moment, however, that is exactly what they are.
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consumers, free of charge, wherever dietary supplements are sold. This report would
offer objective study and analysis of dietary supplements and would list those supple-
ments that have been proven safe and effective for particular problems.
This solution would discourage irresponsible marketing of products, which
manufacturers know to be unsafe or ineffective, and would encourage companies to
fund objective studies that would be accepted by FDA as sufficient proof of safety and
efficacy. Contrast this commercial incentive for objective studies with the current lan-
guage requiring that materials accompanying a product must simply present a "bal-
anced view of the available scientific information," a standard which makes no re-
quirement that the available information be credible." The information would allow
consumers to choose to purchase those supplements proven safe and effective, but
would not restrict their freedom to purchase other supplements if they wish to do so.
This solution is a compromise between the premarket approval model rejected by
Congress and the current policing model in which FDA only has the power to remove
those products which it can affirmatively prove are dangerous. FDA would retain the
ability to remove dangerous products, and simply would be providing additional in-
formation to consumers.' 65This plan effectively would divide the available products
into three classes: 1) those proven safe, or safe and effective, which would be listed in
the FDA publication; 2) those proven unsafe, which would be removed by FDA; 3)
those about which sufficient information is not yet available, which would be avail-
able for purchase at the consumer's risk. The list could also provide information about
certain companies or brands that have shown that they repeatedly meet standards of
consistency and purity in their products, as part of the safety evaluation. And it could
inform consumers that certain products only should be taken under physician supervi-
sion, and/or that certain products should not be taken by individuals with certain
conditions (e.g., pregnancy).
This solution appears to strike a balance between goals of consumer protection,
availability of information and potentially helpful products, and would provide effec-
tive market incentives toward those goals. As stated above, however, it will be diffi-
cult to convince Congress of the need for changes in the direction of safety and protec-
tion, absent some well-publicized consumer tragedy. It is unfortunate that consumers
should be required to wait for a catastrophe to create sound policy.
4 108 Stat. 4329 (DSHEA § 5); 21 U.S.C. § 343B(a)(3) (emphasis added).
65 This strategy also avoids the current judicial concern about conflicts between the First Amendment and
FDA's traditional posture of controlling information about products regulated by the agency.
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